

HANDOUT C

Good morning, Representative. I have a couple quick notes for you and am happy to attend the next meeting of the Committee to discuss further.

Regarding Leqembi, the drug mentioned in the Democrat Gazette letter to the editor, we do cover for an initial approval duration of 3 months (6 doses of infusion) and the drug must be prescribed by or in consultation with a geriatrician or neurologist. There are a few requirements for authorization. Namely, documented presence of beta amyloid, functional and cognitive tests, etc. General standard documentation for approval.

Regarding the prospect of new drugs entering the market: they are all evaluated by our Pharmacy & Therapeutics Committee and the evidence reviewed as far as safety and efficacy. Then a decision is made whether to include based on that and, if so, should they require a prior authorization or not.

As far the availability of new drugs entering the market, that is outside of our control.

I am happy to attend the next meeting after discussion today, but the bottom line is that our plans are covering Leqembi.

Jack Hopkins
Manager, Government Relations
Operations
501-725-7755
David.J.Hopkins@centene.com
ARHealthWellness.com
ArkansasTotalCare.com



arkansas
health & wellness.



arkansas
total care.

Helping Arkansas Live Better

P.O. Box 25538 | Little Rock, AR 72221